Af­ter purg­ing its own can­di­dates, Mer­ck says it's ready to as­sist in Covid-19 vac­cine pro­duc­tion

Days af­ter quash­ing high hopes of a late but re­li­able ad­di­tion to the glob­al Covid-19 vac­cine menu, Mer­ck is search­ing for a way back to the ac­tion.

Hav­ing pi­o­neered im­por­tant im­mu­niza­tions in pub­lic health emer­gen­cies over the decades — de­vel­op­ing shots for mumps, chick­en pox and more re­cent­ly Ebo­la — Mer­ck ex­ecs now say they are will­ing to open up their in­fra­struc­ture in ser­vice of vac­cines de­vel­oped by bio­phar­ma ri­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER